Logo 1 Logo 2

Clinical Trial Details

Trial ID: L0032
Source ID: NCT06560801
Associated Drug: Dapagliflozin 10mg Tab
Title: Dapagliflozin on Renal Morphology and Renal Perfusion in Patients One Year After Kidney Transplantation
Acronym:
Status: RECRUITING
Study Results: NO
Results:
Conditions: Chronic Kidney Diseases
Interventions: DRUG: Dapagliflozin 10mg Tab
Outcome Measures: Primary: renal morphology - fibroblasts, integrity of peritubular fibroblasts (PDGFRα) assessed from the routine one year follow up biopsy of the renal transplant, 3 months after randomization|renal morphology - inflammation, markers of inflammation (example CD3, CD68, CD163) in the interstitium from the routine one year follow up biopsy of the renal transplant, 3 months after randomization|renal morphology - oxidative stress, markers of oxidative stress (Nox1, 8-OHdG) in the interstitium assessed from the routine one year follow up biopsy of the renal transplant, 3 months after randomization | Secondary: mRNA Expression profile of transcripts, mRNA Expression profile of transcripts relevant in renal transplantation using the Human Organ Transplant Panel of NanoString including 770 genes., 3 months after randomization|renal perfusion, renal perfusion of the renal transplant measured by ASL-MRI, 3 months after randomization|central (aortic) systolic pressurepulse pressure, central (aortic) systolic pressure and pulse pressure, 3 months after randomization|pulse pressure, pulse pressure, 3 months after randomization
Sponsor/Collaborators: Sponsor: University of Erlangen-Nürnberg Medical School
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE4
Enrollment: 48
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2023-07-28
Completion Date: 2026-12-31
Results First Posted:
Last Update Posted: 2024-08-19
Locations: Clinical Research Center (CRC), Erlangen, Bavaria, 91054, Germany
URL: https://clinicaltrials.gov/show/NCT06560801